SPC322
Luspatercept
Status:
VeittApplication date:
18.12.2020Application published:
15.1.2021Grant published:
15.4.2022
Max expiry date:
12.8.2034Medicine name:
ReblozylMedicine for children:
No
Timeline
Today
18.12.2020Application
15.1.2021Publication
15.4.2022Registration
12.8.2034Expires
Marketing license
IS authorization number:
EU/1/20/1452/001 & EU/1/20/1452/002Date:
20.7.2020
Foreign authorization number:
EU/1/20/1452Date:
25.6.2020
Owner
Name:
Acceleron Pharma Inc.Address:
128 Sidney Street, Cambridge, MA US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2340031